Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo

BMC Cancer

Volumn 2, Issue , 2002, Pages

  Seely, B Lynn ^a   Samimi, Goli ^b   Webster, Nicholas J G ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RECEPTOR ANTIBODY; SOMATOMEDIN C RECEPTOR; AKT1 PROTEIN, HUMAN; GROWTH INHIBITOR; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL TRANSFORMATION; CHO CELL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN PHOSPHORYLATION; RETROVIRUS; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL LINE; CENTRAL NERVOUS SYSTEM TUMOR; ENZYMOLOGY; GENETICS; HAMSTER; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL LINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHO CELLS; CRICETINAE; GENE EXPRESSION REGULATION, VIRAL; GLIOBLASTOMA; GROWTH INHIBITORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RETROVIRIDAE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 3042798431     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-2-15     Document Type: Article

References (57)

1. Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999, 274:8347-8350
2. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675
3. Cantrell DA: Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001, 114:1439-1445
4. Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999, 253:239-254
5. Leslie NR, Downes CP: PTEN: The down side of PI 3-kinase signalling. Cellular Signalling 2002, 14:285-295
6. Maehama T, Dixon JE: PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999, 9:125-128
7. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999, 96:4240-4245
8. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16:64-67
9. Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999, 91:1922-1932
10. Dahia PL: PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000, 7:115-129
11. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, et al: Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999, 59:2551-2556
12. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390
13. Yamada KM, Araki M: Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001, 114:2375-2382
14. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997, 57:5221-5225
15. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999, 96:2110-2115
16. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, et al: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998, 8:1169-1178
17. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000, 60:3605-3611
18. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999, 96:1563-1568
19. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. PNAS 2001, 98:10983-10985
20. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927
21. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al: Akt phosphorylation of BAD couples survival signals to the cellintrinsic death machinery. Cell 1997, 91:231-241
22. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689
23. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001, 21:893-901
24. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al: Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321
25. Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M, Bookstein R: Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res 1999, 59:2318-2323
26. Weng LP, Brown JL, Eng C: PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 2001, 10:599-604
27. Winter RN, Kramer A, Borkowski A, Kyprianou N: Loss of Caspase-1 and Caspase-3 Protein Expression in Human Prostate Cancer. Cancer Res 2001, 61:1227-1232
28. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000, 275:10761-10766
29. Scrimgeour AG, Blakesley VA, Stannard BS, LeRoth D: Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology 1997, 138:2552-2558
30. Ni Z, Lou W, Leman ES, Gao AC: Inhibition of Constitutively Activated Stat3 Signaling Pathway Suppresses Growth of Prostate Cancer Cells. Cancer Res 2000, 60:1225-1228
31. Baserga R: The IGF-I receptor in cancer research. Exp Cell Res 1999, 253:1-6
32. LeRoith D, Baserga R, Helman L, Roberts CT: Insulin-like growth factors and cancer. Ann Intern Med 1995, 122:54-59
33. LeRoith D, Werner H, Beitner-Johnson D, Roberts CTJ: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16:143-163
34. Luttrell LM, Van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ: G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J. Biol. Chem. 1995, 270:16495-16498
35. Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH: Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem 1998, 273:28065-28072
36. Accili D, Nakae J, Kim JJ, Park BC, Rother KI: Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. J Pediatr Endocrinol Metab 1999, 12:475-485
37. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 1995, 55:249-252
38. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997, 1332:F105-126
39. Baserga R, Resnicoff M, Dews M: The IGF-I receptor and cancer. Endocrine 1997, 7:99-102
40. Pollak M, Beamer W, Zhang JC: Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1999, 17:1998-383
41. Yee D: The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res. Treat. 1994, 32:85-95
42. Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998, 58:1159-1164
43. Ogino S, Kubo S, Abdul-Karim FW, Cohen ML: Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev Pathol 2001, 4:23-31
44. Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M: Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992, 50:215-222
45. Gammeltoft S, Ballotti R, Nielsen FC, Kowalski A, Van Obberghen E: Receptors for insulin-like growth factors in the central nervous system: structure and function. Horm Metab Res 1988, 20:436-442
46. Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR: The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett 1988, 93:114-119
47. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M: PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 1999, 18:3936-3943
48. Lammers R, Van Obberghen E, Ballotti R, Schlessinger J, Ullrich A: Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. J. Biol. Chem. 1990, 265:16886-16890
49. Treadway JL, Morrison BD, Soos MA, Siddle K, Olefsky J, Ullrich A, et al: Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:214-218
50. Seely BL, Reichart DR, Takata Y, Yip C, Olefsky JM: A functional assessment of insulin/insulin-like growth factor-I hybrid receptors. Endocrinology 1995, 136:1635-1641
51. Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ: Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 1998, 76:223-227
52. Burgaud JL, Resnicoff M, Baserga R: Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem. Biophys. Res. Commun. 1995, 214:475-481
53. Hsu D, Knudson PE, Zapf A, Rolband GC, Olefsky JM: NPXY motif in the insulin-like growth factor-I receptor is required for efficient ligand-mediated receptor internalization and biological signaling. Endocrinology 1994, 134:744-750
54. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, et al: Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998, 58:2331-2334
55. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DG, et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989, 84:1418-1423
56. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, et al: Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas. J Clin Oncol 2001, 19:2189-2200
57. Friedmann T, Yee JK: Pseudotyped retroviral vectors for studies of human gene therapy. Nat. Med. 1995, 1:275-277